摘要
目的探讨三维适形放射治疗(3D-CRT)联合低剂量泽菲单药治疗老年局部晚期非小细胞肺癌的临床疗效,并观察临床不良反应的发生情况。方法收集我院自2006年10月~2009年10月确诊为局部晚期非小细胞肺癌且年龄在60岁以上的患者39例,随机分为对照组(19例)和治疗组(20例);对照组患者给予3D-CRT治疗4周,总量为40~60Gy,每周3次,3~5Gy/次;治疗组患者在给予同等剂量3D-CRT治疗的基础上同时联合单药泽菲治疗,在每周3D-CRT治疗开始前3~4h给予静脉输注泽菲200mg/m2,1次/周,共4周;全部患者均给予常规对症治疗。4周后评价两组患者的临床疗效和并观察不良反应的发生情况。结果治疗组患者的总有效率(总有效率=完全缓解+部分缓解/总人数)为70.0%,显著高于对照组的总有效率(36.8%),差异具有统计学意义(P=0.038);在未终止放化疗的基础上给予药物对症治疗后患者均能耐受,全部患者均未出现休克、死亡等严重不良反应,且两组患者不良反应发生情况相比无显著差异(P=0.431)。结论 3D-CRT联合低剂量泽菲治疗老年局部晚期非小细胞肺癌的近期疗效较好,可显著提高患者近期的总有效率,且无严重的不良反应发生,患者耐受性较好,值得临床推广。
Objective To probe into the clinical efficacy of the combined treatment of 3D-CRT and low-dose single-a-gent gemcitabine in curing locally advanced non-cell lung cancer of elderly patients and to observe the clinical adverse reactions. Methods This research had been conducted through dividing 39 cases into control group (19 cases) and treatment group (20 cases) randomly, all of whom were over 60 years old and had been diagnosed with locally advanced non-cell lung cancer in our hospital during Oct 2006 to Oct 2009; the control group was treated with 3D-CRT for four weeks in a total dosage of 40 to 60 Gy, three times a week and 3 to 5 Gy per time; given the same dose in 3D-CRT therapy combined with single-agent gemc- itabine, the treatment group took 200mg/m2 in 3 to 4 hours before 3D-CRT every week, once per week for 4 weeks. In addition, all patients had obtained routine heteropathy and finally would be evaluated based on the clinical efficacy and adverse reactions after 4 weeks. Results Total effective rate (the total effective rate=complete remission+partial remission/headcount) was 70.0% in treatment group that significantly higher than that in control group (36.8%) with statistical differences; all patients were well- tolerated after taking medical heteropathy on the basis of radiotherapy and chemotherapy without severe adverse reactions like shock and death. Furthermore, there was no obvious difference of adverse reactions in both groups (P=0.431). Conclusion With a good therapeutic effect, the combined treatment of 3D-CRT and low-dose single-agent gemeitabine is worthy to be clinically expanded as it can remarkably improve the patients" total effective rate and toleration without severe adverse reactions.
出处
《中国现代医药杂志》
2011年第12期25-27,共3页
Modern Medicine Journal of China
关键词
非小细胞肺癌
3D-CRT泽菲
同步放化疗
Non-ceil lung cancer 3D-CRT Gemcitabine Concurrent radiotherapy and chemotherapy